Segment and Geographic Information - Reconciliation of Reportable Segment Operating Income (Loss) to Corresponding Consolidated Amounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Segment Reporting Information [Line Items]
Total revenue	$ 555,498	$ 513,703	$ 388,537
Amortization of other intangible assets	32,300	37,400	35,400
Restructuring related charges		13,364	301
Restructuring charges	712	385	674
Operating income (loss)	(24,735)	(31,089)	(36,600)
Interest income	20,286	632	849
Interest expense	(4,589)	(2,037)	(2,944)
Loss on extinguishment of debt	(632)
Other expenses	(266)	(16,475)	(1,597)
Loss before income taxes	(9,936)	(48,969)	(40,292)
Completed Technology
Segment Reporting Information [Line Items]
Amortization of other intangible assets	7,325	8,073	8,099
Acquired Intangible Assets
Segment Reporting Information [Line Items]
Amortization of other intangible assets	24,965	29,299	27,276
Life Sciences Products
Segment Reporting Information [Line Items]
Total revenue	199,230	199,606	129,759
Life Sciences Services
Segment Reporting Information [Line Items]
Total revenue	356,268	314,097	258,778
Operating Segments
Segment Reporting Information [Line Items]
Operating income (loss)	21,817	45,753	(182)
Operating Segments | Life Sciences Products
Segment Reporting Information [Line Items]
Operating income (loss)	11,033	23,094	(3,041)
Operating Segments | Life Sciences Services
Segment Reporting Information [Line Items]
Operating income (loss)	10,784	22,659	2,859
Corporate, Non-Segment
Segment Reporting Information [Line Items]
Other unallocated corporate expense (income)	$ 13,550	$ 25,721	$ 68